| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
BPH-715 targets human recombinant geranylgeranyl diphosphate synthase (GGPPS) with an IC₅₀ of approximately 280.0 nM and farnesyl diphosphate synthase (FPPS) with an IC₅₀ of 100.0 nM. These enzymes are critical in the mevalonate pathway for protein prenylation. By inhibiting GGPPS and FPPS, BPH-715 disrupts the post-translational modification of small GTPases such as Ras and Rho, which are essential for cancer cell proliferation and invasiveness.
|
|---|---|
| ln Vitro |
In vitro, BPH-715 effectively inhibits the growth of tumor cells and suppresses their invasiveness, confirming its potential as an anticancer agent that blocks protein prenylation. It also demonstrates potent activity against Plasmodium liver stages in cell culture, specifically inhibiting the formation of exoerythrocytic forms in HepG2 cells with an IC₅₀ of 10 μM. This dual activity against cancer and malaria parasites highlights its broad therapeutic potential.
|
| ln Vivo |
In vivo studies have shown that BPH-715, as a lipophilic bisphosphonate, has potent activity against Plasmodium liver stages. Its efficacy in animal models of malaria and cancer has been demonstrated, although detailed published data on specific in vivo protocols and results are limited. The compound's ability to inhibit protein prenylation in vivo suggests it can effectively disrupt both tumor growth and parasitic infections.
|
| Enzyme Assay |
For in vitro enzyme assays, BPH-715 is evaluated against human recombinant GGPPS and FPPS. The enzymes are incubated with varying concentrations of the compound and their respective substrates (geranylgeranyl diphosphate or farnesyl diphosphate) in the presence of a radiolabeled tracer. Enzyme activity is measured by quantifying the incorporation of the isoprenoid substrate into a standard acceptor molecule. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
For in vitro cell-based assays, BPH-715 is tested on HepG2 cells infected with Plasmodium to assess inhibition of liver-stage parasite growth. Cells are treated with the compound at various concentrations (typically 0.1-100 μM) for 48-72 hours. Parasite load is quantified by microscopy or qPCR to determine the IC₅₀. Additionally, cancer cell lines are used to evaluate inhibition of cell proliferation and invasiveness using standard MTT and transwell assays.
|
| Animal Protocol |
For in vivo animal experiments, BPH-715 is typically administered to mouse models of malaria or cancer. In malaria models, mice are infected with Plasmodium sporozoites, and the compound is administered via intraperitoneal or oral routes. Parasitemia is monitored by blood smears, and liver-stage burden is assessed by qPCR of liver tissue. In cancer models, tumor xenografts are established in immunocompromised mice, and tumor volume is measured following compound treatment.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for BPH-715 are limited. As a lipophilic bisphosphonate, it is expected to have poor oral bioavailability and is typically administered parenterally. The compound may have a long half-life due to its binding to bone tissue, which is a common property of bisphosphonates. Detailed PK parameters such as Cmax, Tmax, half-life, and AUC have not been extensively published in the available literature.
|
| Toxicity/Toxicokinetics |
Toxicological data for BPH-715 are limited. As a bisphosphonate, it may share some toxicity profile with other drugs in this class, including potential gastrointestinal irritation, nephrotoxicity, and osteonecrosis of the jaw at high doses. However, comprehensive toxicological studies have not been extensively reported. The compound is classified as a research-grade reagent and is not for human therapeutic use.
|
| Additional Infomation |
BPH-715 is a research-use only compound and has not been approved for clinical applications. Its IUPAC name is 2-(3-decoxypyridin-1-ium-1-yl)-1,1-diphosphonoethane inner salt. The compound's unique dual activity against cancer cells and Plasmodium liver stages makes it a valuable research tool. It is also known as BPH715, and its molecular formula and weight are well-characterized. It is available from various research chemical suppliers for non-clinical studies.
|
| Molecular Formula |
C17H31NO7P2
|
|---|---|
| Molecular Weight |
423.37806725502
|
| Exact Mass |
423.158
|
| CAS # |
1059677-23-4
|
| PubChem CID |
25014899
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.613
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
14
|
| Heavy Atom Count |
27
|
| Complexity |
491
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
P(C(C[N+]1C=CC=C(C=1)OCCCCCCCCCC)P(=O)([O-])O)(=O)(O)O
|
| InChi Key |
QYJHUOZDBUEKQC-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H31NO7P2/c1-2-3-4-5-6-7-8-9-13-25-16-11-10-12-18(14-16)15-17(26(19,20)21)27(22,23)24/h10-12,14,17H,2-9,13,15H2,1H3,(H3-,19,20,21,22,23,24)
|
| Chemical Name |
[2-(3-decoxypyridin-1-ium-1-yl)-1-phosphonoethyl]-hydroxyphosphinate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
0.5 M NaOH : 80 mg/mL (~188.96 mM)
DMSO : ~5 mg/mL (~11.81 mM) |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3619 mL | 11.8097 mL | 23.6194 mL | |
| 5 mM | 0.4724 mL | 2.3619 mL | 4.7239 mL | |
| 10 mM | 0.2362 mL | 1.1810 mL | 2.3619 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
